SOURCE: MedaSorb Technologies Corporation

July 18, 2007 10:34 ET

MedaSorb Technologies' Chief Medical Officer Receives "Legends Award" From the Kidney & Urology Foundation of America

MONMOUTH JUNCTION, NJ--(Marketwire - July 18, 2007) - MedaSorb Technologies Corporation (OTCBB: MSBT) today publicly recognized its Chief Medical Officer, James Winchester, for receiving the 2007 "Legends Award" in Nephrology from the Kidney & Urology Foundation of America for his lifelong dedication to excellence in clinical medicine research and medical education.

"We want to congratulate Dr. Winchester for receiving this outstanding award; it is well deserved," said Al Kraus, CEO of MedaSorb. "We are fortunate to have someone of Jim's expertise and accomplishments working to advance MedaSorb's blood purification technology." Dr. Winchester is widely recognized as one of the world's leading experts in hemoperfusion and toxicology.

Dr. Winchester has over 30 years' experience in renal replacement therapy, published more than 200 articles in scientific and medical journals, and co-authored eight books in the fields of renal replacement therapy and clinical poisoning management.

Dr. Winchester joined MedaSorb in 2000 as Chief Medical Officer, and is the Chief of the Nephrology Division at Beth Israel Medical Center. He was Professor of Medicine and Director of Dialysis Programs at Georgetown University School of Medicine for more than 25 years. Dr. Winchester received his medical degree from the University of Glasgow and is a Fellow of the Royal College of Physicians and Surgeons of Glasgow, and a Fellow of the American College of Physicians.

About the Kidney & Urology Foundation of America

The Kidney & Urology Foundation of America, Inc. is a national, not-for-profit organization dedicated to helping people avoid the debilitating effects of kidney and urologic diseases. Each year some 70 million Americans, nearly one in four people, suffer the debilitating effects of these diseases. The financial impact is devastating, the impact to the human spirit, immeasurable.

About MedaSorb

MedaSorb Technologies Corporation is a medical device company, preparing to commercialize blood purification technology that effectively removes toxic compounds from circulating blood. MedaSorb's initial product, CytoSorb™, known medically as a hemoperfusion device incorporates our proprietary adsorbent polymer technology. Management believes the potential healthcare applications for its products include adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short- and long-term treatment of kidney failure. MedaSorb is headquartered in Monmouth Junction, New Jersey.

Safe Harbor Statement

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Quarterly Report on Form 10-QSB filed with the SEC on May15, 2007, which is available at

Contact Information